Rezdiffra (Resmetirom): What People Actually Pay

What Is the List Price of Rezdiffra?

Madrigal Pharmaceuticals set Rezdiffra's wholesale acquisition cost (WAC) at approximately $47,400 annually, which translates to about $3,950 per month at full retail. This figure places the drug in the mid-range for specialty hepatology medications but well above generic liver disease treatments like vitamin E or off-label pioglitazone. The WAC does not reflect what most patients pay at the pharmacy counter, however, because rebates, insurance formulary placement, and manufacturer assistance programs reduce the actual out-of-pocket burden substantially for many users.

The FDA's approval announcement on March 14, 2024 made Rezdiffra the first therapy specifically indicated for MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced fibrosis (F2-F3). That distinction matters for pricing, because payers have no generic alternative to reference. Before Rezdiffra, the only pharmacological option with trial data in MASH was off-label vitamin E or pioglitazone, both available for under $30 per month. This gap between the old standard and the new price tag creates friction during coverage determinations, which patients feel directly in the form of prior authorization delays and step-therapy requirements [1].

How Much Do Commercially Insured Patients Actually Pay?

The short answer for most patients with commercial insurance: between $0 and $50 per month, provided they enroll in Madrigal's CareConnect copay assistance program. That program covers up to $13,000 per year in out-of-pocket costs and is available to patients with private or employer-sponsored insurance who meet eligibility criteria. Several patients on Reddit and liver disease forums have confirmed receiving the drug at zero copay after enrollment.

Without the copay card, the picture changes. Commercially insured patients assigned to specialty tiers report coinsurance obligations between 25% and 33%, which can mean monthly costs of $988 to $1,304 before reaching their plan's out-of-pocket maximum. One hepatology patient forum user described a $1,100 initial pharmacy quote before the copay card was applied. Another reported that their specialty pharmacy quoted $4,200 for a 30-day supply when processed without any discount program, a figure consistent with the WAC.

The timing also matters. Patients whose plans reset deductibles on January 1 may face higher costs in Q1 before accumulator or maximizer programs kick in. Some plans use copay accumulator adjustment programs that prevent manufacturer copay assistance from counting toward the patient's annual deductible or out-of-pocket maximum [2]. In those cases, patients could exhaust the $13,000 annual copay card benefit and still owe thousands more before reaching their plan's ceiling.

What Does Medicare Part D Coverage Look Like?

Medicare Part D patients face a different cost equation because manufacturer copay cards cannot be used with federal insurance programs. Rezdiffra's specialty-tier placement in most Part D formularies means patients are responsible for 25% coinsurance during the initial coverage phase, which can produce a monthly cost near $988 at list price before any plan-specific negotiation.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (effective January 2025) provides a ceiling, but patients may hit that cap within the first few months of Rezdiffra therapy. After reaching $2,000, the patient owes nothing for the remainder of the calendar year. This means Medicare patients on Rezdiffra may effectively pay $2,000 annually for the drug, spread across roughly two to three months of cost-sharing before the cap takes effect.

Madrigal's CareConnect patient assistance program does offer a separate track for Medicare patients who demonstrate financial need, though eligibility thresholds and approval rates are not publicly disclosed. Dr. Zobair Younossi, a hepatologist at Inova Fairfax Medical Campus who has published extensively on MASH health economics, noted in a 2024 commentary that "the real-world affordability of MASH therapies will depend less on list price and more on how quickly payers build clinical pathways that connect diagnosed patients to coverage" [3].

How Do Prior Authorization Requirements Affect Access?

Nearly every major payer requires prior authorization for Rezdiffra, and the criteria are stricter than many patients expect. Standard requirements include biopsy-confirmed MASH with fibrosis stage F2 or F3, documented by a pathologist within the preceding 12 to 24 months. Some plans accept FibroScan (vibration-controlled transient elastography) results showing liver stiffness values consistent with significant fibrosis (typically 8.0 to 12.0 kPa for F2, 12.0 to 14.0 kPa for F3), but others insist on histological confirmation via liver biopsy.

This biopsy requirement creates a bottleneck. Liver biopsy carries a small but real risk of complications, costs between $3,000 and $7,000 depending on facility and insurance, and requires scheduling that can add weeks or months to the prior authorization timeline. Patients in online forums frequently describe a frustrating cycle: their hepatologist diagnoses MASH clinically, prescribes Rezdiffra, and the insurer denies coverage pending a biopsy the patient has not yet undergone or is reluctant to pursue.

Dr. Mary Rinella, a hepatologist at the University of Chicago and co-author of the AASLD MASH guidance, observed that "we are in a period where diagnostic requirements for drug access lag behind clinical practice, and patients pay the price in delays" [4]. Step-therapy requirements adding a mandatory trial of lifestyle intervention or vitamin E before Rezdiffra approval are also common and can extend the gap between diagnosis and treatment initiation by three to six months.

What Did MAESTRO-NASH Show About Efficacy?

The Phase 3 MAESTRO-NASH trial (N=966) randomized patients with biopsy-confirmed MASH and F1B to F3 fibrosis to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks. At week 52 to 25.9% of patients on resmetirom 80 mg and 29.9% on resmetirom 100 mg achieved MASH resolution with no worsening of fibrosis, compared to 9.7% on placebo (P<0.001 for both doses vs. placebo). For fibrosis improvement by at least one stage with no worsening of the NAFLD activity score, the rates were 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% for placebo [1].

These histological endpoints are meaningful because fibrosis stage is the strongest predictor of liver-related mortality in MASH. A 2019 meta-analysis of 1,495 patients published in Gastroenterology found that each one-stage increase in fibrosis was associated with a 58% increase in all-cause mortality and a 2.5-fold increase in liver-related mortality [5]. Reversing or halting fibrosis progression is the clinical goal that justifies Rezdiffra's price point in payer negotiations.

LDL cholesterol also dropped by 13% to 16% in the resmetirom arms versus placebo, an effect consistent with resmetirom's mechanism as a thyroid hormone receptor-beta (THR-beta) agonist that increases hepatic fat metabolism and lowers atherogenic lipoproteins [1]. This secondary cardiovascular benefit has not yet been tested in an outcomes trial, but it may influence long-term cost-effectiveness analyses.

What Are Patients Saying Online About Cost and Experience?

Patient-reported experiences on Reddit (r/liver, r/NAFLD, and scattered posts in r/Semaglutide), Drugs.com, and liver disease forums remain limited in volume. Rezdiffra has been on the market for just over two years, and the diagnosed MASH population with biopsy-confirmed F2-F3 fibrosis is smaller and less active online than the GLP-1 user community.

Among the reports that do exist, several themes recur. Patients who successfully enrolled in Madrigal's copay program describe $0 monthly costs, and most express surprise at how quickly the enrollment process worked relative to the prior authorization itself. A handful of patients report that their specialty pharmacy required a new prescription every 90 days, adding administrative friction.

Side effects mentioned in patient posts align with the MAESTRO-NASH safety data: diarrhea (reported in 27% of the 100 mg arm vs. 13.3% placebo), nausea (17.8% vs. 8.7%), and occasional reports of mild GI discomfort that resolved within the first four to six weeks [1]. Several users noted that GI side effects were milder than they expected based on reading the prescribing information. Lab monitoring requirements (thyroid function, lipid panel, liver enzymes every three months in the first year) add to indirect costs that patients rarely mention online but that accumulate to several hundred dollars annually depending on insurance.

Selection bias is significant in these reports. Patients who obtained insurance approval, enrolled in copay assistance, and tolerated the drug are overrepresented. Those denied coverage, unable to afford cost-sharing, or who discontinued due to side effects are less likely to post. The total number of identifiable unique patient reports online as of mid-2026 is likely fewer than 200, a sample too small to draw population-level conclusions about affordability or satisfaction.

How Does Rezdiffra's Cost Compare to Other Liver Disease Therapies?

Rezdiffra occupies an unusual niche. It is the only FDA-approved drug for MASH, which means direct drug-to-drug price comparisons within the indication do not exist. Against the broader liver disease formulary, context helps. Obeticholic acid (Ocaliva), which was under review for MASH but received a complete response letter in 2023, had a projected annual cost near $70,000. GLP-1 receptor agonists like semaglutide, which show promise in MASH trials but lack the specific indication, cost $12,000 to $16,000 per year at list price for the 2.4 mg weight-management dose.

Vitamin E (800 IU daily) and pioglitazone (30 to 45 mg daily), the two off-label options with the most MASH trial data, cost under $360 per year combined. Neither has demonstrated the histological fibrosis improvement that Rezdiffra achieved in MAESTRO-NASH, but the price gap of more than 100-fold means payers frequently require a trial of these agents before approving Rezdiffra. The AASLD's 2023 practice guidance acknowledges vitamin E for non-diabetic MASH patients but does not position it as equivalent to resmetirom in fibrosis reversal [4].

For patients with MASH who also qualify for GLP-1 therapy due to obesity or type 2 diabetes, prescribers sometimes sequence semaglutide first (addressing metabolic drivers) and add Rezdiffra if fibrosis persists. This combination strategy is not yet validated in a completed trial, though the ongoing MAESTRO-NASH-OUTCOMES extension study may provide relevant data. The combined annual drug cost would exceed $60,000 at list price for both agents.

What Financial Assistance Options Exist?

Madrigal's CareConnect program is the primary patient support pathway and includes three tracks. Commercially insured patients can access a copay card covering up to $13,000 per year in out-of-pocket costs. Uninsured patients may qualify for free drug supply through the patient assistance program after demonstrating income below 500% of the federal poverty level. Medicare and Medicaid patients can request assistance through a separate needs-based evaluation.

Independent charitable foundations, including the Patient Access Network Foundation (PAN Foundation) and HealthWell Foundation, had not opened dedicated Rezdiffra funds as of early 2026. This may change as prescribing volume grows and manufacturer contributions to these foundations increase. Specialty pharmacies like Accredo and AllianceRx Walgreens report offering benefits investigation services that can identify alternative coverage pathways for patients initially denied.

Dr. Samer Gawrieh, a hepatologist at Indiana University School of Medicine and MAESTRO-NASH investigator, stated in a 2024 interview: "Access to resmetirom depends on three things in practice. The diagnosis must be documented with the specificity payers require, the prescriber must be willing to manage prior authorization, and the patient must connect with financial support before abandoning the prescription" [6].

What Should Patients Expect in the First 90 Days?

The first three months of Rezdiffra therapy involve a predictable sequence. After prior authorization approval, the specialty pharmacy ships the medication (typically a 30-day supply). Patients start at 80 mg daily if body weight is below 100 kg, or 100 mg daily if at or above 100 kg. Baseline labs should include a comprehensive metabolic panel, TSH, free T4, and a lipid panel [7].

GI side effects peak in weeks two through four and typically improve by week six. LDL cholesterol reductions become measurable on the first follow-up lipid panel at week 12. Liver enzyme decreases (ALT, AST) often appear within four to eight weeks. Histological improvement, the endpoint that determines whether to continue therapy, cannot be assessed until at least week 52, which means patients commit to a full year before the drug's primary benefit is evaluated by biopsy or imaging.

The repeat biopsy or FibroScan at 12 months adds another $800 to $7 to 000 in costs depending on the method and insurance plan. Patients should confirm with their insurer before starting therapy whether the 12-month assessment will be covered and which modality (biopsy vs. elastography) the plan will accept for continued authorization. Thyroid function monitoring (TSH and free T4) is recommended at baseline, 4 to 8 weeks, and then every 6 to 12 months, per the prescribing information [7].